Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)

Blood

Volumn 121, Issue 8, 2013, Pages 1479-1481

  Qiao, Jianlin ^a   Schoenwaelder, Simone M ^a   Mason, Kylie D ^b   Tran, Huy ^b   Davis, Amanda K ^c   Kaplan, Zane S ^a   Jackson, Shaun P ^a   Kile, Benjamin T ^d   Andrews, Robert K ^a   Roberts, Andrew W ^b   Gardiner, Elizabeth E ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; CD9 ANTIGEN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN VI; INTEGRIN ALPHA2B BETA3; NAVITOCLAX; STEROID; TETRASPANIN; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

CELL LEVEL; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LETTER; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; STEROID THERAPY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA;

EID: 84874410120     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-467415     Document Type: Letter

References (11)

1. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113(2):299-305.
2. Hillmen P. Targeted therapy for chronic lymphocytic leukemia: A glimpse into the future. J Clin Oncol. 2012;30(5):469-470.
3. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavail-able Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
4. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186. (Pubitemid 46427871)
5. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of Navito-clax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
6. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL inhibitory BH3 mi-metics can induce a transient thrombocytopathy that undermines the hemo-static function of platelets. Blood. 2011;118:1663-1674.
7. ClinicalTrials.gov. NCT 00788684. A phase 1 study evaluating the safety of ABT-263 in combination with rituximab in subjects with CD20-positive lymphoid malignancies. http://clinicaltrialsgov/ct2/show/NCT00788684. Accessed May 16, 2012.
8. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009;20(3):143-149.
9. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloprotei-nase. Blood. 2004;104(12):3611-3617. (Pubitemid 39564435)
10. Al-Tamimi M, Arthur JF, Gardiner EE, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost. 2012;107(4):648-655.
11. Visco C, Ruggeri M, Evangelista L, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111(3):1110-1116. (Pubitemid 351213389)